Snips, Full article: http://www.news-medical.net/?id=37998
The 5,000 square-foot, $5 million pilot and commercial-scale manufacturing plant will be used to produce vaccines addressing a broad range of infectious diseases. The facility will initially supply influenza vaccine for the company's current clinical programs with planned annual capacity of 10 million doses.
"Our production technology, which can be used to produce many types of vaccines in a single facility, combined with our use of disposable materials, offer the potential advantage of simple portability of production equipment to sites around the world, where vaccines may be urgently needed."
Novavax has four proprietary vaccine candidates in development addressing pandemic influenza, seasonal flu, varicella zoster and an undisclosed infectious disease target. The company's lead vaccine candidate to protect against pandemic influenza is currently in Phase II clinical testing.
The 5,000 square-foot, $5 million pilot and commercial-scale manufacturing plant will be used to produce vaccines addressing a broad range of infectious diseases. The facility will initially supply influenza vaccine for the company's current clinical programs with planned annual capacity of 10 million doses.
"Our production technology, which can be used to produce many types of vaccines in a single facility, combined with our use of disposable materials, offer the potential advantage of simple portability of production equipment to sites around the world, where vaccines may be urgently needed."
Novavax has four proprietary vaccine candidates in development addressing pandemic influenza, seasonal flu, varicella zoster and an undisclosed infectious disease target. The company's lead vaccine candidate to protect against pandemic influenza is currently in Phase II clinical testing.